Genetic Factors on Outcomes of Kidney Transplant Patients With Tacrolimus-based Therapy

The Influence of Genetic and Clinical Factors on Clinical Outcomes of Kidney Transplant Patients With Tacrolimus Based Immunosuppression

The purpose of this study is to identify the influence of genetic and clinical factors on the clinical outcomes of kidney transplant patients with tacrolimus (TAC) based immunosuppression in Taiwan.

Tacrolimus (TAC) is the most important immunosuppressants for maintenance therapy after kidney transplantation. Many genetic and clinical factors had been found to have effect on TAC pharmacokinetics (PK). Whether these factors affect clinical outcomes is still controversial.

In this retrospective study, investigators will review records of kidney transplant patients with TAC based immunosuppression recruited from a previous study (IRB approval number: 201512005RINC) to understand the influence of clinical and genetic factors on their 3-years clinical outcomes, including biopsy-proven acute rejection, patient survival, graft survival and safety issues of kidney transplant patients.

Inclusion Criteria:

1. Kidney transplantation
2. 20-65 years old
3. Receiving tacrolimus-based immunosuppressants
4. Were recruited in a previous trial

Exclusion Criteria:

1. Human immunodeficiency virus-positive status
2. Retransplantation or multiorgan transplantation
3. Non-Asian